BioSpace News Archive

Sequana Medical NV announces positive results from its Phase 1 single-center, single-arm, single-dose trial with its second-generation DSR product.

Immunovia, the diagnostics company that has launched the world’s first blood-based test dedicated to the early detection of pancreatic cancer, announced the appointment of Karl Stone as Chief Operating Officer effective 1 March, 2023.

Atreca, Inc. today announced that John A. Orwin, President and Chief Executive Officer, will be participating in a panel discussion focused on novel oncology targets at Cowen’s 43rd Annual Health Care Conference on March 7, 2023.

BeyondSpring Inc. today announced that the first patient has been enrolled in BeyondSpring’s Phase 2 investigator-initiated trial with lead asset, Plinabulin, in combination with Merck’s anti-PD-1 therapy Keytruda® (pembrolizumab) and Docetaxel for previously treated patients with metastatic non-small cell lung cancer (NSCLC) and progressive disease after immunotherapy (anti-PD-1 / PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced financial results for the fiscal quarter ended December 31, 2022.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and year ended December 31, 2022, after the close of the market on Wednesday, March 8, 2023.

Royal Philips, a global leader in health technology, announced its radiology portfolio of smart connected imaging systems and vendor-neutral integrated radiology workflow solutions featured at the European Congress of Radiology international meeting.

ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced a collaboration with mProbe, Inc. (“mProbe”), a precision health and medicine company utilizing clinical proteomics in the oncology space, and Dr. Christopher Hartley of Mayo Clinic for the continued development of its BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences.

Global biotechnology leader CSL (ASX:CSL;USOTC:CSLLY), announced that The Lancet has published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE).